Dr. Wang Discusses Acalabrutinib in MCL
Michael Wang, MD
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma (MCL).
Acalabrutinib is a second-generation BTK inhibitor that was recently approved by the FDA for the treatment of adult patients with MCL following at least 1 prior therapy.
Wang says that targeted therapies should not be underestimated in this disease, as they are a very powerful alternative to chemotherapy.